CME 5 Session – EANM’12

(2)

Diagnosis and Therapy of Neuroblastoma

Educational objectives:

  1. To present the current concept of neuroblastoma tumor characteristics with its variable biological behaviour
  2. To give an overview of current diagnostic and therapeutic management of neuroblastoma patients
  3. To understand the historical development of I-131-mIBG therapy and its current use in high-risk neuroblastoma
  4. To address important aspects how to deliver I-131-mIBG therapy in a pediatric population
Summary:
This session is designed for those nuclear medicine specialists and residents with interest in paediatric oncology. It is the aim to give an overview about diagnostic methods and current treatment strategies of neuroblastoma patients.
Neuroblastoma, the most common extracranial solid tumour entity in childhood, requires a number of imaging modalities for precise staging.
Different imaging strategies with SPECT/CT, either with or without intravenous contrast administration, PET/CT and PET in combination with MRI at diagnosis and in follow-up will be discussed. A special focus will be on the role of MIBG scintigraphy and alternative imaging methods (esp. PET with different radiotracers).
Patients are divided into different risk groups requiring highly different treatment modalities. High-risk neuroblastoma patients are in the need to undergo a highly intensive chemotherapy regimen.
Especially in this high-risk group, a large number of studies are needed for diagnosis and response assessment. Autologous stem-cell transplantation has become a key element in the treatment of these patients and I-131-mIBG therapy may play an important role in this scenario.

Key Words:
Pediatric Oncology, Neuroblastoma, SPECT/CT, PET/CT, MIBG Therapy

User action required
If you have the permission to view this publication, please log in.

Login